NDA 205582 · Sun Pharm
Decitabine
Decitabine · Intravenous
DiscontinuedLast checked: Nov 20, 2026Latest source record: Sep 16, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2014
Jan 23, 2014
Approved uses
1
Original approval plus efficacy supplements
Registered trials
538
69 Phase 3, 82 recruiting
FAERS reports
4,367
4,145 serious, 1,166 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 23, 2020.
Decitabine for Injection is indicated for treatment of adult patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups. Decitabine for Injection is a nucleoside metabolic inhibitor indicated for treatment of adult patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups. (1)
Mechanism: Decitabine is believed to exert its antineoplastic effects after phosphorylation and direct incorporation into DNA and inhibition of DNA methyltransferase, causing hypomethylation of DNA and cellular differentiation or apoptosis. Decitabine inhibits DNA methylation in vitro, which is achieved at concentrations that do not cause major suppression of DNA synthesis. Decitabine-induced hypomethylation in neoplastic cells may restore normal function to genes that are critical for the control of cellular differentiation and proliferation. In rapidly dividing cells, the cytotoxicity of decitabine...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 23, 2014 Original approval · Type 5 - New Formulation or New Manufacturer Summary ReviewLetterLabel
1 products under this application
- DECITABINE · DECITABINE 50MG/VIAL · POWDER, INTRAVENOUS · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Decitabine" as an intervention, any sponsor and status, largest first.
- Study of Biomarker-Based Treatment of Acute Myeloid LeukemiaPivotal-lookingRecruiting
Beat AML, LLCAcademic, hospital or other
NCT03013998 · 3,000 participants (planned) · Start Nov 2016 · Primary completion Dec 2032
Drug: Samalizumab (BAML-16-001-S1); BI 836858 (BAML-16-001-S2) and 45 more · For: Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Sites: Phoenix, Arizona; Scottsdale, Arizona; Los Angeles, California · 31 sites in all
National Cancer Institute (NCI)NIH
NCT05564390 · 2,000 participants (planned) · Start Jun 18, 2024 · Primary completion May 15, 2029
Drug: Azacitidine; Azacitidine and 18 more · For: Acute Myeloid Leukemia; Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm; Acute Myeloid Leukemia Post Cytotoxic Therapy and 2 more
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 360 sites in all
- Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy CombinationsPivotal-lookingStatus unknown
Cardiff UniversityAcademic, hospital or other
NCT02272478 · 1,600 participants (planned) · Start Oct 30, 2014 · Primary completion Feb 2021
Drug: Arm A Mylotarg plus DA Versus CPX-351; Arm B Vosaroxin and Decitabine and 4 more · For: Acute Myeloid Leukaemia; Myelodysplastic Syndrome
Sites: Aalborg, Denmark; Aarhus, Denmark; Copenhagen, Denmark · 87 sites in all
- Genotype-guided Treatment in DLBCLPivotal-lookingStatus unknown
Ruijin HospitalAcademic, hospital or other
NCT05351346 · 1,100 participants (planned) · Start Jun 1, 2022 · Primary completion Jun 1, 2026
Drug: Rituximab; Cyclophosphamide and 6 more · For: Diffuse Large B Cell Lymphoma
Sites: Shanghai, China
- SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission InductionPivotal-lookingCompleted
Astex Pharmaceuticals, Inc.Industry
NCT02348489 · 815 participants · Start Mar 19, 2015 · Primary completion May 31, 2018
Drug: SGI-110 (guadecitabine); Treatment Choice · For: Leukemia, Myeloid, Acute
Sites: Scottsdale, Arizona; La Jolla, California; Los Angeles, California · 135 sites in all
- Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid LeukemiaPivotal-lookingCompleted
ECOG-ACRIN Cancer Research GroupResearch network
NCT02085408 · 727 participants · Start Feb 4, 2011 · Primary completion Feb 22, 2021
Drug: Daunorubicin; Cytarabine and 2 more · For: Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0) and 14 more
Sites: Birmingham, Alabama; Scottsdale, Arizona; Tucson, Arizona · 269 sites in all
- "InDACtion" vs "3+7" Induction in AMLPivotal-lookingStatus unknown
European Organisation for Research and Treatment of Cancer - EORTCResearch network
NCT02172872 · 606 participants · Start Nov 28, 2014 · Primary completion Mar 7, 2022
Drug: standard combination chemotherapy; decitabine · For: Acute Myeloid Leukemia (AML)
Sites: Edegem, Belgium; Jette, Belgium; Verviers, Belgium · 53 sites in all
- A PALG Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in AML Patients ≤ 60 Years OldPivotal-lookingStatus unknown
Polish Adult Leukemia GroupAcademic, hospital or other
NCT03257241 · 582 participants (planned) · Start Jul 3, 2017 · Primary completion Apr 1, 2022
Drug: A arm (DA-90); B arm (DAC) and 2 more · For: Acute Myeloid Leukemia
Sites: New York, New York; Bialystok, Poland; Brzozów, Poland · 10 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use508
- febrile neutropenia456
- myelosuppression438
- drug ineffective349
- neutropenia334
- pneumonia325
- thrombocytopenia291
- death287
- pyrexia263
- acute myeloid leukaemia242
- anaemia218
- product use in unapproved indication218
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 7 |
| 2008 | 11 |
| 2009 | 43 |
| 2010 | 29 |
| 2011 | 123 |
| 2012 | 132 |
| 2013 | 86 |
| 2014 | 75 |
| 2015 | 75 |
| 2016 | 103 |
| 2017 | 172 |
| 2018 | 249 |
| 2019 | 322 |
| 2020 | 491 |
| 2021 | 451 |
| 2022 | 517 |
| 2023 | 452 |
| 2024 | 367 |
| 2025 | 343 |
| 2026 | 317 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Decitabine (Decitabine)
2024 spending
$361K
Beneficiaries
59
305 claims
Per beneficiary
$6,117
$281.57 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $586,669 |
| 2021 | $739,607 |
| 2022 | $771,638 |
| 2023 | $570,000 |
| 2024 | $360,887 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AML.
Lu J, Xue SL, Wang Y, et al. · Blood 2025 · Randomized Controlled Trial, Multicenter Study
- A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort.
Goldfinger M, Mantzaris I, Shastri A, et al. · Blood 2024 · Clinical Trial
- All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia.
Roboz GJ, Zeidan AM, Mannis GN, et al. · N Engl J Med 2026 · Multicenter Study, Clinical Trial, Phase II
- Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study.
Garcia-Manero G, McCloskey J, Griffiths EA, et al. · Lancet Haematol 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study.
Bazinet A, Garcia-Manero G, Short N, et al. · Lancet Haematol 2024 · Clinical Trial, Phase II
- Oral decitabine-cedazuridine in acute myeloid leukaemia.
Bouligny IM, DiNardo CD · Br J Haematol 2024 · Randomized Controlled Trial
Sponsor: Sun Pharm
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.